Form 4: Lexicon Pharma CMO Converts RSUs, Adjusts Holdings

Lexicon Pharmaceuticals' SVP and Chief Medical Officer, Craig B. Granowitz, reported the conversion of restricted stock units into common stock and a subsequent sale to cover tax obligations.

Summary

• Craig B. Granowitz, SVP and Chief Medical Officer of Lexicon Pharmaceuticals, reported changes in his beneficial ownership of common stock.
• On February 28, 2026, Granowitz acquired a total of 312,276 shares of common stock through the exercise/conversion of Restricted Stock Units (RSUs) (35,790 + 74,226 + 202,260 shares).
• Concurrently, he disposed of 109,098 shares of common stock at a price of $1.47 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Granowitz directly beneficially owns 323,430 shares of common stock.
• Remaining Restricted Stock Units after these transactions include 74,227 and 404,520 units, which represent contingent rights to receive common stock.
• RSUs vest with respect to 1/3 of the shares on February 28 of each of the three years following the year of grant.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While there's a sale of shares, it's for tax purposes related to RSU vesting, which is a routine compensation event and indicates continued executive equity ownership.

Positives

• The conversion of Restricted Stock Units into common stock indicates the vesting of previously granted equity compensation, aligning management's interests with shareholders.
• The increase in direct beneficial ownership of common stock to 323,430 shares demonstrates continued executive stake in the company's performance.

Negatives

• The disposal of 109,098 shares of common stock, valued at $1.47 per share, to cover tax withholding obligations represents a reduction in the executive's direct shareholding, albeit for a standard tax-related purpose.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving the vesting and subsequent tax-related sale of restricted stock units, are common occurrences in the biotechnology and pharmaceutical sectors. These transactions typically reflect pre-scheduled equity compensation plans rather than discretionary trading based on new material information. The vesting of RSUs is a standard mechanism to align executive incentives with long-term company performance.

Comparison to Industry Standards

• Form 4 filings primarily report individual insider transactions and do not typically provide data for direct comparison to industry-wide financial benchmarks or specific competitor results.
• The reported RSU vesting schedule (1/3 annually over three years) is a common structure for executive equity compensation across various industries, including biotech, similar to practices seen at companies like Amgen or Gilead Sciences, which use similar long-term incentive structures to retain and motivate key personnel.

Related Party Transactions

• Vesting of Restricted Stock Units and subsequent share disposal for tax withholding between Lexicon Pharmaceuticals, Inc. and its SVP, Chief Medical Officer, Craig B. Granowitz.

Stakeholder Impact

• Shareholders: The transactions reflect routine executive compensation and do not indicate a significant shift in company strategy or financial health. The executive's continued ownership aligns interests.
• Employees: No direct impact on general employees is indicated.

Next Steps

• Future vesting of remaining Restricted Stock Units on February 28 of subsequent years, as per the 1/3 annual vesting schedule.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to the vesting of Restricted Stock Units and a subsequent sale to cover tax obligations. Such events are pre-scheduled and do not typically signal a change in the company's fundamental outlook or performance. Therefore, it provides no new information to warrant a change in investment stance, suggesting a 'hold' recommendation for investors already positioned in LXRX.

Keywords

Lexicon Pharmaceuticals, LXRX, Form 4, Insider Trading, Restricted Stock Units, Equity Compensation, Craig B. Granowitz, Officer Transactions, Stock Ownership